PAFAH1B2 Antibody

What is PAFAH1B2 and what cellular functions does it perform?

PAFAH1B2 (Platelet Activating Factor Acetylhydrolase 1b Catalytic Subunit 2) is the beta subunit of the cytosolic type I platelet-activating factor acetylhydrolase (PAF-AH) heterotetrameric enzyme. It functions as an alpha2 catalytic subunit that hydrolyzes the acetyl group at the sn-2 position of platelet-activating factor (PAF) and its analogs, thereby modulating PAF activity .

The protein is involved in several key cellular processes:

• Regulation of inflammatory responses through PAF inactivation

• Possible role in male germ cell meiosis during late pachytene stage and meiotic divisions

• Early spermiogenesis functions (based on similarity studies)

• Potential role in Alzheimer's disease pathology by influencing amyloid-β levels

The activity and substrate specificity of PAF-AH (I) vary depending on its subunit composition:

• The alpha2/alpha2 homodimer (PAFAH1B2/PAFAH1B2) efficiently hydrolyzes PAF and 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylethanolamine (AAGPE)

• The alpha1/alpha2 heterodimer (PAFAH1B3/PAFAH1B2) preferentially hydrolyzes 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoric acid (AAGPA)

What are the standard applications for PAFAH1B2 antibodies in research?

PAFAH1B2 antibodies are versatile tools utilized across multiple experimental platforms:

Researchers should note that optimal dilutions may vary based on specific experimental conditions and should be empirically determined for each application and sample type .

What species reactivity do commonly available PAFAH1B2 antibodies exhibit?

Based on the search results, commercially available PAFAH1B2 antibodies primarily demonstrate reactivity with:

• Human samples

• Mouse samples

• Rat samples (for some antibodies)

For example, the polyclonal antibody (14729-1-AP) has been validated for both human and mouse samples in Western blot and immunoprecipitation applications . When planning experiments with other species, cross-reactivity should be validated before proceeding with full-scale studies.

How should researchers validate PAFAH1B2 antibody specificity in their experimental systems?

Proper validation of PAFAH1B2 antibodies is critical for experimental reliability. A comprehensive validation approach should include:

• Knockout/Knockdown Controls:

  • Use PAFAH1B2 knockout or knockdown cell lines as negative controls

  • Example: Lentiviral PAFAH1B2-targeting shRNA has been successfully used to generate stable knockdown in ovarian cancer cell lines (MCAS, SKOV3, OV432, RMGUL)

  • Validate knockdown efficiency by Western blot as described in previous studies

• Recombinant Protein Controls:

  • Test antibody against purified recombinant PAFAH1B2 protein

  • Compare with structurally similar proteins (e.g., PAFAH1B3) to assess cross-reactivity

• Multiple Detection Methods:

  • Confirm findings using at least two independent detection methods (e.g., WB and IHC)

  • Example: Studies have successfully used both Western blotting and immunohistochemistry to detect PAFAH1B2 in ovarian cancer samples

• Peptide Competition Assay:

  • Pre-incubate antibody with purified PAFAH1B2 peptide before application

  • Signal should be significantly reduced if antibody is specific

  • Neutralizing peptides are commercially available for this purpose

• Mass Spectrometry Verification:

  • For absolute confirmation, immunoprecipitate with PAFAH1B2 antibody and analyze by mass spectrometry

What methodological approaches are most effective for studying PAFAH1B2 interactions with LIS1 (PAFAH1B1)?

PAFAH1B2 has been shown to interact with PAFAH1B1 (LIS1) , and studying this interaction requires specific methodological approaches:

• Co-immunoprecipitation (Co-IP) Strategy:

  • Immunoprecipitate using PAFAH1B2 antibody (e.g., 14729-1-AP at 0.5-4.0 μg per 1.0-3.0 mg of total protein lysate)

  • Probe Western blots with anti-LIS1 antibody

  • Include appropriate controls (IgG control, input lysate)

• Expression Analysis in Mutant Models:

  • Research has shown that PAFAH1B2 deletion affects LIS1 protein levels in testis tissue

  • LIS1 protein levels were reduced in LIS1+/- testis but markedly elevated in α2-/- (PAFAH1B2 knockout) testis

  • This approach can reveal functional relationships between the proteins

• Proximity Ligation Assay (PLA):

  • For in situ detection of PAFAH1B2-LIS1 interactions in fixed cells/tissues

  • Requires pairs of antibodies targeting each protein

  • Provides spatial information about interaction events

• Fluorescence Resonance Energy Transfer (FRET):

  • For real-time monitoring of protein-protein interactions

  • Requires fluorescent tagging of both PAFAH1B2 and LIS1

  • Can be performed in live cells to capture dynamic interactions

What are the key considerations when using PAFAH1B2 antibodies for cancer research applications?

PAFAH1B2 has demonstrated significant relevance in cancer research, particularly:

• Selection of Appropriate Cancer Models:

  • PAFAH1B3 (close paralog of PAFAH1B2) shows elevated expression in multiple human cancers

  • Studies have successfully used PAFAH1B2 antibodies in:

    • Ovarian cancer tissues and cell lines (MCAS, SKOV3)

    • Liver hepatocellular carcinoma

    • Endometrial cancer

    • Colon cancer

    • Glioma

• Experimental Design for Functional Studies:

  • PAFAH1B2 knockdown approaches have shown:

    • Significant inhibition of cancer cell proliferation

    • Reduced migration and tumorigenicity

    • Activation of caspases

    • Cell cycle arrest

  • These endpoints should be measured alongside PAFAH1B2 expression

• Consideration of Immunological Context:

  • PAFAH1B3 expression correlates with immune cell infiltration in 27-30 different cancer types

  • Expression positively associates with immune checkpoint-related genes (CD274, CTLA4, etc.)

  • This suggests immune regulatory functions that may also apply to PAFAH1B2

• Tissue Microarray Analysis Approach:

  • For high-throughput screening of PAFAH1B2 expression across tumor samples

  • Example protocol:

    • Deparaffinize in xylene and rehydrate through graded alcohols

    • Retrieve antigens by boiling for 3 minutes in pressure pot

    • Block endogenous peroxidases with 3% hydrogen peroxide (10 min)

    • Incubate with PAFAH1B2 antibody (e.g., 20365-1-AP) overnight at 4°C

    • Use peroxidase-conjugated secondary antibody (37°C, 30 min)

    • Develop with DAB substrate and counterstain with hematoxylin

How can researchers troubleshoot non-specific bands or inconsistent results when using PAFAH1B2 antibodies?

When encountering technical issues with PAFAH1B2 antibodies, consider these troubleshooting approaches:

• For Non-specific Bands in Western Blotting:

  • Increase blocking time and concentration (5% non-fat milk or BSA in TBST)

  • Optimize primary antibody concentration (try serial dilutions from 1:200 to 1:2000)

  • Increase washing steps (5-6 times, 5 minutes each with TBST)

  • Try different PAFAH1B2 antibodies (e.g., comparing 14729-1-AP, sc-393217, or ab238828)

  • Run known positive controls (e.g., human testis tissue, mouse small intestine tissue)

• For Weak or Absent Signal:

  • Verify sample preparation (complete lysis, protease inhibitors included)

  • Check protein concentration by BCA or Bradford assay

  • Increase sample loading amount

  • Reduce washing stringency

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced detection systems (e.g., chemiluminescent substrates with longer exposure times)

• For Inconsistent IP Results:

  • Optimize lysis buffer composition (detergent type and concentration)

  • Adjust antibody-to-protein ratio (0.5-4.0 μg antibody per 1.0-3.0 mg total protein)

  • Pre-clear lysates with protein A/G beads

  • Cross-link antibody to beads to reduce IgG contamination

  • Extend incubation time (overnight at 4°C with gentle rotation)

• For Background in IHC/ICC:

  • Optimize antigen retrieval conditions

  • Block with serum from the same species as secondary antibody

  • Include 0.1-0.3% Triton X-100 in blocking solution

  • Use more dilute antibody solution (start with 1:100 and titrate)

  • Include appropriate controls (isotype, secondary only, known negative tissue)

What are the optimal methods for detecting PAFAH1B2 splice variants in experimental samples?

Research has identified a novel splice variant of PAFAH1B2 with potentially important functional implications . To detect and study such variants:

• RT-PCR Strategy for Splice Variant Detection:

  • Design primers spanning exon junctions (particularly targeting the exon 5-7 junction)

  • The novel PAFAH1B2 splice variant lacks exon 6 and includes an alternative exon 7

  • PCR conditions should be optimized for specificity and sensitivity

  • Analyze products using high-resolution gel electrophoresis

• 3′ RACE Methodology:

  • For confirmation of exon 5 to 7 splice and exon 7 polyadenylation

  • Previous research successfully used this approach to characterize the splice variant

  • Sequence the resulting products to verify splice junctions

• Western Blot Analysis for Protein Isoforms:

  • Use antibodies targeting epitopes in conserved regions (e.g., N-terminal domains)

  • The splice variant protein has shown a distinct band pattern in liver tissue

  • Compare with computational predictions of molecular weight differences

  • Consider higher percentage gels (12-15%) for better resolution of similar-sized isoforms

• Tissue-Specific Expression Analysis:

  • The splice variant has been observed in human liver, monocytes, T cells, and B lymphocytes

  • Compare expression levels across multiple tissue types

  • Use quantitative PCR to determine relative abundance of canonical vs. splice variant forms

How can PAFAH1B2 antibodies be effectively used to investigate its role in Alzheimer's disease pathology?

PAFAH1B2 has been implicated in Alzheimer's disease through its effects on amyloid-β (Aβ) generation . Researchers investigating this connection should consider:

• Experimental Design for Aβ Generation Studies:

  • RNAi-mediated knockdown of PAFAH1B2 has been shown to significantly reduce Aβ secretion

  • Compare with its homolog PAFAH1B3, which does not show the same effect

  • Monitor APP C-terminal fragments (CTFs), as PAFAH1B2 appears to specifically affect their degradation

• Cross-Species Model Systems:

  • Effects were initially identified in Drosophila S2 cells expressing human APP βCTF

  • Findings were replicated in mammalian cells and primary cells from PAFAH1B2 knockout mice

  • Consider using multiple model systems for translational relevance

• Co-localization Studies:

  • Use PAFAH1B2 antibodies in combination with APP/Aβ antibodies

  • Perform double immunofluorescence staining in brain tissue samples

  • Analyze using confocal microscopy to determine spatial relationships

• Practical Protocol for Human Brain Tissue Analysis:

  • Fix human brain tissue in 4% paraformaldehyde

  • Perform antigen retrieval using citrate buffer (pH 6.0)

  • Block with 5% normal goat serum

  • Incubate with PAFAH1B2 primary antibody (1:100 dilution, overnight at 4°C)

  • Apply fluorescent secondary antibody (1:500, 1 hour at room temperature)

  • Counterstain with DAPI and mount with anti-fade medium

  • Analyze using fluorescence microscopy

How can PAFAH1B2 antibodies be utilized to explore its potential role in inflammation and immune regulation?

PAFAH1B2's function in hydrolyzing PAF suggests important roles in inflammation and immune regulation:

• Experimental Approach for Studying Inflammatory Pathways:

  • The alternative splice variant of PAFAH1B2 (lacking exon 6) may reduce the protein's ability to function as a regulator of inflammation

  • Compare PAFAH1B2 expression and localization in resting vs. activated immune cells

  • Measure PAF levels in samples with varying PAFAH1B2 expression

  • Correlate PAFAH1B2 expression with inflammatory markers

• Protocol for Immune Cell Activation Studies:

  • Isolate peripheral blood mononuclear cells (PBMCs)

  • Activate with appropriate stimuli (e.g., LPS, PMA/ionomycin)

  • Collect samples at various time points post-activation

  • Analyze PAFAH1B2 expression by Western blot and immunofluorescence

  • Compare canonical vs. splice variant expression

• Analysis in Inflammatory Disease Models:

  • PAFAH1B2 has been associated with inflammatory bowel disease 28

  • Use PAFAH1B2 antibodies to assess expression in inflamed vs. normal tissues

  • Consider dual staining with inflammatory cell markers (CD68, CD3, etc.)

  • Correlate with disease severity indices

What methodologies are recommended for investigating PAFAH1B2's role in aspirin metabolism?

Research has identified PAFAH1B2 as an erythrocyte aspirin hydrolase, with significant implications for aspirin's antiplatelet effects :

• Aspirin Hydrolysis Assay Protocol:

  • Erythrocyte PAFAH1B2 has been shown to hydrolyze aspirin, and this activity is competitively inhibited by PAF

  • Recombinant PAFAH1B2, but not plasma PAF acetylhydrolase, demonstrates aspirin hydrolysis activity

  • For in vitro assays:

    • Incubate purified PAFAH1B2 or erythrocyte lysates with aspirin

    • Measure hydrolysis products by HPLC or spectrophotometric methods

    • Include PAF as a competitive inhibitor control

    • Use NaF (type I PAF acetylhydrolase inhibitor) as a positive control for inhibition

• Cell-Based Experimental Design:

  • Transfect HEK cells with PAFAH1B2 or PAFAH1B3 expression constructs

  • Assess aspirin hydrolysis in transfected vs. control cells

  • Measure effects on downstream aspirin targets (e.g., COX inhibition)

  • Use PAFAH1B2 antibodies to confirm expression levels

• Platelet Function Analysis:

  • Pre-expose aspirin to erythrocytes (which contain PAFAH1B2)

  • Test the pre-exposed aspirin's ability to inhibit thromboxane A2 synthesis

  • Assess effects on platelet aggregation

  • Compare with fresh aspirin as a control

How should researchers design experiments to investigate the neurodevelopmental roles of PAFAH1B2?

PAFAH1B2 has connections to neurodevelopmental conditions through its interaction with LIS1 (PAFAH1B1) and associations with intellectual disability :

• Recommended Experimental Models:

  • PAFAH1B2 knockout or conditional knockout mice

  • Human iPSC-derived neural progenitors with PAFAH1B2 manipulation

  • Brain organoids with CRISPR-modified PAFAH1B2

• Neurodevelopmental Assessment Protocol:

  • Perform detailed histological analysis of brain development

  • Use PAFAH1B2 antibodies in combination with neural markers (Nestin, DCX, NeuN)

  • Assess migration patterns of neurons using BrdU labeling

  • Examine dendritic arborization and synapse formation

• Molecular Interaction Studies:

  • Investigate PAFAH1B2 interactions with PAFAH1B1 (LIS1), which is critical for neuronal migration

  • Use proximity ligation assays to detect interactions in situ

  • Perform co-immunoprecipitation followed by mass spectrometry to identify novel interaction partners

• Relationship to Autism Spectrum Disorders:

  • PAFAH1B2 has been identified as an ASD candidate gene (SFARI Gene Score: 2)

  • Two de novo missense variants and one de novo frameshift variant have been observed in ASD probands

  • TADA analysis identified PAFAH1B2 as an ASD candidate gene with q-value < 0.1

  • Design experiments comparing variant and wild-type PAFAH1B2 function